Introduction
Helicobacter pylori is a Gram-negative, microaerophilic, spiral-shaped bacterium that chronically infects the stomach. This pathogen is associated with chronic gastritis and gastric ulcer and may lead to the development of gastric cancer (Uemura et al., 2001) . Despite the observed production of specific antibodies to H. pylori and recruitment of various cell populations to inflamed gastric areas, the infection remains life-long. Infection with H. pylori is one of the most common bacterial infections worldwide. To date, numerous virulence factors responsible for gastric colonization, survival and tissue damage have been described and characterized (Dubreuil et al., 2002) . However, the critical feature of this infection may reside in its ability to persist within the host for such a long period of time and not in its ability to damage host tissues. Many of the pathogenic events seen during H. pylori infection may be due to alteration of the host response by the bacterium. Interactions with various host serum and extracellular matrix proteins have been related to the infectious process (Dubreuil et al., 2002) . Some of these interactions, as with heparin and heparan sulfate, are of high affinity (K d ¼ 9 3 10 À9 M) (Ascensio et al., 1995) and could therefore play a crucial role in the fate of the pathogenic process. The interplay of host proteins binding to H. pylori could represent an effective way to evade the host immunological response and to adapt to an invading infection.
Heparin is produced by mast cells and is stored in intracellular granules. It is found particularly in liver, lungs and gut of various animals. A structural relative, heparan sulfate, is found in the extracellular cell matrix at the surface of most animal cells. This acidic glycosaminoglycan is produced by both epithelial and mesenchymal cells. It is less sulfated than heparin. Recent studies indicate that H. pylori may favour the interaction with heparin, as the availability of this component may be enhanced in epithelial and subepithelial environment. Neutrophil-activating protein produced by this bacterium is able to cross the epithelial layer and subsequently activates mast cells, followed by degranulation and release of the granule content (Montemurro et al., 2002) . Recently, vacuolating cytotoxin A (VacA) was also shown to recruit and activate mast cells (Sapajatura et al., 2002) . The C-terminal domain of the 58 kDa subunit of H. pylori VacA binds heparin and heparan sulfate (Utt et al., 2001) , indicating that heparan sulfate could represent a receptor/ coreceptor for VacA cytotoxin, supporting the results of an earlier study (Reyrat et al., 1999) . Experiments with cells in culture showed inhibition of cell vacuolation following pretreatment of H. pylori with heparin (Sommi et al., 1997) . A heparin-binding protein was located at the cell surface by biotinylation and indirect immunofluorescence assays. This protein corresponded to a 55-60 kDa molecule (Utt & Wadstrom, 1997 terial recruitment of molecules, such as heparin, in the immediate environment during the infectious process. These molecules can then serve as universal binding sites for various mammalian heparin-binding proteins. Ascensio et al. (1995) have shown clearly that pre-incubation of H. pylori with heparan sulfate and other sulfated polysaccharides resulted in enhanced fibroblast growth factor binding, supporting this novel microbial pathogenesis strategy.
We performed a study to determine whether the binding of heparin, a glycosaminoglycan found in many animal tissues and known to bind to H. pylori with high affinity, could alter the survival of the micro-organism in the presence of serum.
Methods
Bacterial strains and culture media. H. pylori strains SPM 326, CCUG 17874
T and Sidney strain 1 (SS1) (Lee et al., 1997) were used in this study. Strain SPM 326 was obtained from a human isolate that was adapted to the mouse as described previously (Marchetti et al., 1995) . All H. pylori strains tested are cytotoxin-associated antigen A (CagA)-positive (Xiang et al., 1995) . Bacteria were grown for 24 h on Columbia agar plates under microaerophilic conditions as described previously (Xiang et al., 1995) .
Normal rabbit serum. Fresh rabbit blood was collected from naive rabbits (a pool of three animals). The blood was centrifuged to sediment the cells and then filtered on 0 . 22 ìm filters. When tested, the sera did not react with H. pylori whole-cell extract, as determined by immunoblot. Sera were kept for 7 days at most. Complement components were inactivated by heating the serum at 56 8C for 30 min.
Serum bactericidal assay. A modification of the bactericidal assays reported by Ngeleka et al. (1992) and Trust et al. (1981) was employed. Briefly, H. pylori was grown overnight on Petri plates and the growth scraped from the solid medium. Cells were washed twice in Veronal solution (4 . 1 g NaCl, 0 . 5 g gelatin, 0 . 5 g sodium 5,5-barbiturate, in 500 ml water, after adjusting the pH to 7 . 35 with HCl and adding 0 . 5 ml each of 2 M MgCl 2 and 0 . 3 M CaCl 2 ). The cell suspension was adjusted to an OD 535 of 1 (approx. 10 9 c.f.u. ml À1 ). Various quantities of heparin (sodium salt from porcine intestinal mucosa; Sigma) ranging from 0 to 10 mg ml À1 were added to 200 ìl of 1 : 100-diluted bacterial cell suspension and left for 30 min at 37 8C. Unbound heparin was then removed by washing with 1 . 5 ml Veronal buffer. This step was repeated twice. Next, 200 ìl cell suspension was mixed with 200 ìl of either fresh rabbit serum, heated serum or Veronal buffer, as a negative control. The tubes were incubated for 6 h in a microaerophilic atmosphere (CampyGen, Oxoid). Next, diluted aliquots (50 ìl) were spread on Columbia agar plates and incubated at 37 8C for 72 h under microaerophilic conditions. Various concentrations of heparin were added in order to assess the effect of binding on bacterial survival in the presence of serum. Colony-forming units (c.f.u.) were determined for the different treatments.
Results and Discussion
In this study, we analysed the effect of heparin binding to H. pylori on survival in vitro in the presence of fresh serum. As H. pylori could be exposed to heparin during a gastric infection in vivo and since it is already known that it can bind to this bacterium, it was hypothesized that the process could be responsible, in part, for the augmented survival necessary for long-term establishment in an animal host.
For strain SPM 326, we observed that, in the presence of normal rabbit serum (without antibodies directed against H. pylori), the number of c.f.u. was reduced by about one logarithm in 6 h (Fig. 1a) . No reduction or increase in c.f.u. was noted when cells were incubated in Veronal buffer (data not shown). The viability of this strain was also affected, though to a lesser extent, by addition of heated serum (56 8C for 30 min). Survival of the same strain in the presence of heparin (0 . 2 mg ml À1 ) was much greater in the presence of normal untreated or heated serum. There was a clear protective effect upon heparin addition. No change in c.f.u. was noted when heparin-treated bacterial cells were incubated for 6 h in the presence of heat-treated serum (complement-inactivated) . No bacterial growth was noted for any of the treatments tested. The same general response was noted with strain SS1, with comparable numbers of c.f.u. (data not shown).
We observed similar results for H. pylori CCUG 17874 T (Fig.  1b) . In this case, survival was reduced by almost two logarithms in the absence of heparin when incubated in normal serum. In contrast, in the presence of complementinactivated serum, a one log reduction was noted. Thus, it T (b) in fresh rabbit serum in the absence or presence of 0 . 2 mg heparin ml À1 after 6 h. n, Serum; m, complement-inactivated serum; h, serum plus heparin; j, complement-inactivated serum plus heparin. C.f.u. were determined by plating bacterial cells on Columbia agar plates and incubating at 37 8C for 72 h under microaerophilic conditions. seems that strain CCGU 17874
T is more sensitive to fresh rabbit serum with or without complement. Nevertheless, the protection provided by the addition of heparin (0 . 2 mg ml À1 ) was important and of the same order of magnitude as noted for strains SPM 326 and SS1. Dose-response curves for heparin protection were prepared with strains SPM 326 and CCGU 17874 T (Fig. 2) . When 0 . 1 mg heparin ml À1 was added, no significant protection was seen compared with a control to which no heparin was added. Protection from the normal serum effect was seen at 0 . 2 mg ml À1 and above. Maximal protection was attained at around 0 . 5 mg ml À1 .
The observations that H. pylori strains are susceptible to complement (Gonzales-Valencia et al., 1996) even in the absence of specific antibodies and that heparin binds several complement proteins (Sahu & Pangburn, 1993) could explain, in part, the protective effect noted in our study. It could contribute to immobilization of complement components by heparin that are no longer capable of effectively killing bacterial cells. For example, C4b, in particular, has been shown to bind heparin effectively (Blom, 2002) . This complement protein subunit of the classical pathway can be captured on the surface of several pathogens, including Neisseria gonorrhoeae, Bordetella pertussis, Streptococcus pyogenes and Escherichia coli. This process could contribute to their resistance to serum and increased pathogenicity. The increase in resistance to serum observed in the presence of heparin could indicate a role in resistance to the alternative complement pathway. It is unlikely that heparin mediates binding to C3b, as this complement component was shown not to bind to heparin using radiolabelled compounds and affinity chromatography (Sahu & Pangburn, 1993) . It is possible that heparin masks sites for binding of C3b and blocks initiation of the alternative complement pathway. Thus, limited access for the terminal membrane attack complex to the bacterial cell surface, provided by heparin binding, could be responsible for the serum protection observed.
Nevertheless, as some protection was also observed for heated serum (complement-inactivated), a mechanism other than complement protection seems to be responsible for part of the protection observed. In this study, the amounts of heparin that effectively increased survival of H. pylori are in the range available in vivo, as reported by Lovich & Edelman (1999) , who concluded that approximately 0 . 3 mg ml À1 is found in arteries. It should also be noted that the amount added to bacterial cells did not exclude the fact that only a portion of the heparin added could bind to H. pylori cells effectively in the 30 min period allowed for the reaction to take place. In vivo, longer contact, through H. pylori heparinbinding proteins, could allow concentration of this compound on the surface of the micro-organism to concentrations much above that found in tissues. As heparin could allow H. pylori to avoid phagocytosis (Chmiela et al., 1997) , in vivo studies could reflect this process, which was not evaluated in the present study.
Studies should now be conducted in an animal model for H. pylori to confirm the results generated in this study. This approach could be troublesome, since the differential survival rate of bacteria in vivo could result in more rapid and efficient colonization, but not necessarily in the presence or absence of infection. 
